Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year Low – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL) hit a new 52-week low during trading on Monday . The stock traded as low as $1.86 and last traded at $1.88, with a volume of 258277 shares trading hands. The stock had previously closed at $1.95.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

The company has a market cap of $506.90 million, a price-to-earnings ratio of -1.57 and a beta of 2.02. The company’s 50 day moving average price is $2.23 and its 200 day moving average price is $3.18.

Institutional Trading of Autolus Therapeutics

Several large investors have recently made changes to their positions in AUTL. Virtus ETF Advisers LLC lifted its holdings in Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after purchasing an additional 6,081 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after buying an additional 8,479 shares during the last quarter. Bellevue Group AG lifted its stake in shares of Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after buying an additional 9,000 shares during the last quarter. State Street Corp boosted its holdings in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after buying an additional 10,401 shares during the period. Finally, Barclays PLC grew its stake in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after buying an additional 10,866 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.